From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Presidential highlights
Professor Christine Gennigens, a distinguished medical oncologist at CHU de Liège, has provided an in-depth overview of the GCIG INTERLACE trial, which was presented during the presidential session at the
Prof Christine Gennigens, a medical oncologist at CHU de Liège, conducted an interview with Prof Emeritus Ignace Vergote, a gynaecological oncologist at University Hospitals Leuven, who had the honour of
Daily highlights in gynaeco
Laure-Anne Teuwen, a medical oncologist at the University Hospital of Antwerp, presents a selection of key studies in the field of gynaecological cancer discussed at ESMO 2023.
A phase II dose expansion study of Luvelta, an antibody-drug conjugate
Prof Dr Els Van Nieuwenhuysen presents the latest findings from the proffered paper session at ESMO23.
The FLAMES study, a phase 3 investigation involving randomized controlled patients afflicted with advanced ovarian cancer, unveiled the outcomes of administering
In-depth stories about gynaeco
The AdvanTIG-202 study represents an open-label phase 2 clinical trial conducted on patients with recurrent or metastatic cervical cancer. The study aimed to assess the effectiveness of a combined therapy
Medical oncologist Prof Christine Gennigens from CHU de Liège and gynaeco-oncologist Prof Els Van Nieuwenhuysen, the last author of the complete publication of the DUO-E/GOG-3041/ENGOT-EN10 trial in JCO 2023, shared
Prof Ramez Eskander, a gynaecological oncologist at the University of California, San Diego, provided a comprehensive overview of the NRG-GY018 trial, a phase 3 randomised placebo-controlled international study to assess
Prof Christine Gennigens, a medical oncologist at CHU de Liège, and Prof Els Van Nieuwenhuysen, a gynaeco-oncologist at UZ Leuven, recently discussed the results of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial, which investigated
With the educational support of: